Latest news with #Rinvoq
Business Upturn
2 days ago
- Health
- Business Upturn
Rheumatologists Eye AbbVie's Rinvoq, Roche/Genentech's Gazyva, and Bristol Myers Squibb's Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports
EXTON, PA, July 23, 2025 (GLOBE NEWSWIRE) — Biologic use in systemic lupus erythematosus (SLE) is steadily rising, with U.S. rheumatologists now treating close to 40% of their moderate-to-severe patients with biologics. Most expect this number to increase as comfort with existing therapies grows and new treatment options become available. GlaxoSmithKline's Benlysta continues to lead the SLE biologic market, though AstraZeneca's Saphnelo is gaining share—especially in patients with cutaneous manifestations. The anticipated launch of a subcutaneous formulation is expected to further accelerate uptake, with rheumatologists projecting notable growth following approval. Despite these gains, most prescribers continue to highlight substantial gaps in care. Fatigue remains the top unmet symptom across the SLE population, and long-term steroid use is still common, despite guideline recommendations and widespread prescriber agreement on their risks. Over three-quarters of rheumatologists agree that currently available options do not adequately support treatment goals in all patient segments—particularly among those with refractory disease or renal involvement. 'For me, the dream is a therapeutic regimen with no corticosteroids,' one physician emphasized. 'That's still the biggest frustration—having to use steroids when flares hit, even if we taper fast.' Others underscored a broader desire for therapies that achieve true remission. 'We need a drug that doesn't just suppress symptoms but can lead to remission—and ideally, drug-free remission.' Interest in the SLE pipeline is strong, particularly for AbbVie's Rinvoq (upadacitinib), Bristol Myers Squibb's Sotyktu (deucravacitinib), and Roche/Genentech's Gazyva (obinutuzumab). Rheumatologists believe these therapies could meaningfully expand the treatment landscape. Both Rinvoq and Sotyktu are viewed as attractive oral options in a market dominated by infusions and injectables, with strong cross-indication familiarity helping drive prescriber confidence. Gazyva, already supported by positive data in lupus nephritis (LN), is expected to play a key role in patients with renal involvement if approved. Litifilimab (developed by Biogen) is also on rheumatologists' radar. The therapy's novel mechanism of action and convenient monthly subcutaneous dosing contribute to high interest. Most prescribers report they would consider it for a sizable portion of their SLE population, especially those who prefer injectables over oral agents or infusions. Similarly, ianalumab (Novartis) and CD40 ligand inhibitors are generating early enthusiasm as potential next-generation biologics, particularly in patients who have cycled through multiple treatment lines. When evaluating emerging therapies, most rheumatologists define a meaningful advance over placebo as at least a 20–35% difference in response, depending on the endpoint used. Based on available Phase 2 trial data, litifilimab stands out for surpassing that threshold in SRI-4. Looking ahead to potential head-to-head clinical trials, Benlysta is viewed as the most appropriate active comparator by a wide margin, selected by over 80% of rheumatologists, far outpacing preferences for Saphnelo or off-label rituximab. These benchmarks highlight how prescribers are contextualizing new agents within existing efficacy standards and where they see real differentiation emerging. Looking further ahead, CAR T-cell therapy represents one of the most potentially disruptive innovations in SLE. While still in early clinical development, more than half of rheumatologists expect this modality to play a leading or definite role in future treatment. On average, prescribers estimate that up to one in six of their current patients could ultimately be candidates for a cell-based therapy. Among those expressing interest, the greatest perceived value lies in its potential to induce sustained or even drug-free remission—something current therapies rarely, if ever, achieve. Prescribing behavior is also shifting in preparation for these advancements. Most rheumatologists now report initiating biologics earlier in the disease course, particularly in patients who fail to reach treatment goals within the first few months of standard therapy. Rather than sequentially adding a conventional DMARD such as azathioprine to hydroxychloroquine (HCQ), many are moving directly to biologics given the severity of lupus and the cumulative damage associated with long-term steroid exposure. Biologics such as Benlysta and Saphnelo are increasingly being layered onto conventional regimens after a short trial of HCQ and corticosteroids, reflecting a more aggressive, target-driven approach to management. As these pipeline therapies advance toward potential approval, Spherix will continue monitoring how clinical perceptions and prescribing behaviors evolve. A pipeline refresh study launching this fall will provide updated insights on rheumatologist sentiment, expected adoption trajectories, and market preparedness as the next wave of SLE innovation approaches. In addition, Spherix will be publishing a companion study, Special Topix™: Cell Therapy in Rheumatology later this summer, focused specifically on the evolving role of cell therapy in rheumatology, including physician awareness, expectations, and potential barriers to adoption. Special Topix™ is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Health Line
17-07-2025
- Health
- Health Line
Does Medicare Cover Rinvoq?
Doctors prescribe Rinvoq (upadacitinib) to treat certain inflammatory conditions, such as rheumatoid arthritis (RA) and ulcerative colitis (UC). It's available as an extended-release oral tablet and an oral solution known as Rinvoq LQ. Rinvvoq belongs to the drug class known as Janus kinase (JAK) inhibitors. Generally, Medicare drug plans can cover Rinvoq. But whether they do or not and how much you must pay out of pocket depends on the specific plan. Which Medicare plan covers Rinvoq? You can get Medicare coverage for prescription drugs via a stand-alone Medicare Part D or a Medicare Advantage prescription drug (MAPD) plan. Private insurers manage these plans and set their coverage and costs. According to the manufacturer's website, experts have performed clinical trials involving Rinvoq for more than 11 years and have prescribed it to more than 100,000 people for RA in the United States since 2019. With both types of drug coverage, your plan must cover at least two drugs from commonly prescribed drug categories. This means that Medicare drug plans may cover them. If they don't, they often cover alternative drugs within the same categories with similar effectiveness. You can check whether your specific plan covers Rinvoq by examining the plan's formulary, which lists all the drugs the plan covers. How much is a 30-day supply of Rinvoq? Without insurance, Rinvoq is a pricey drug. As of 2025, the list cost of a 30-day supply of the drug is $6,752.77. If your Medicare drug plan covers the drug, how much you pay out of pocket depends on the drug's tier within the plan's formulary. Generally, generic drugs tend to be in lower tiers, costing less. However, currently there's no generic version of Rinvoq. That said, under a Medicare drug plan, you may never pay more than $2,000 out of pocket on prescription drugs per year in 2025. Once you reach this amount, your plan may cover the rest of your annual cost in full. This limit changes from year to year. In 2026, it may rise to $2,100. In addition, no Medicare drug plan deductible can be higher than $590 in 2025.
Medical News Today
16-07-2025
- Health
- Medical News Today
Can someone with rheumatoid arthritis donate plasma?
According to the Memorial Sloan Kettering Cancer Center (MSKCC), rheumatoid arthritis (RA) does not generally disqualify a person from donating if a person has severe RA, their doctor may recommend that they do not donate. Other factors unrelated to RA may also stop a person with this condition from being able to example, some factors that may stop a person from donating include:taking aspirin in the past 48 hourstesting positive for HIVcurrent severe allergiestaking antibiotics, excluding antibiotics for acnetaking narcotic pain relieversa current flu or coldhaving routine dental work in the past 24 hourspregnancyweighing below 110 lbsThe MSKCC also states that someone with RA should inform their donor program before donating if they have previously taken or are currently taking upadacitinib (Rinvoq).Upadactinib is a disease-modifying antirheumatic drug (DMARD) that doctors typically use to treat taking immunosuppressive drugs may also be unable to donate blood or plasma, temporarily or permanently. This is due to the increased risk of infection and potential effects on people who will receive the who want to donate plasma may have to undergo medical testing to ensure they are suitable. This may involve testing blood pressure and other health factors. People can speak with a healthcare professional to learn more about this with RA may also want to consider whether the donation process may affect their symptoms or cause discomfort before the needle is in place during plasma donation, a person must recline on a chair and may need to repeatedly squeeze a soft ball. If someone's RA affects their hands or wrists, this action may be entire process of giving plasma may take up to two hours on a person's first time. After this, appointments may range from an hour to an hour and a half. The actual plasma extraction can be up to an hour someone with RA wants to donate plasma, it is generally a good idea to speak with a member of their healthcare team. A healthcare professional can help assess whether they may be a suitable donor and explain the potential for adverse effects or moreEverything to know about rheumatoid arthritisAdvantages and disadvantages of donating bloodFacts about blood plasmaHow does RA affect different parts of the body?
Yahoo
08-07-2025
- Business
- Yahoo
AbbVie to Acquire Capstan Therapeutics for $2.1B, Boosting Autoimmune Pipeline
AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie announced its intention to acquire Capstan Therapeutics in a deal valued at up to $2.1 billion in cash. The acquisition will expand AbbVie's product pipeline, particularly in experimental treatments for autoimmune diseases. Capstan Therapeutics Inc. is a clinical-stage biotechnology company that specializes in developing CAR-T therapies. These therapies use a patient's immune cells, specifically T-cells, to combat diseases. The lead asset is CPTX2309, which is currently in early-stage (Phase 1) clinical development for B-cell-mediated autoimmune diseases. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie will also acquire Capstan's CellSeeker tLNP platform technology, which is designed to deliver RNA payloads, such as mRNA, to engineer cell types in vivo. AbbVie is already projected to make over $31 billion in sales by 2027 with its autoimmune drugs Skyrizi and Rinvoq combined. AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that researches, develops, manufactures, commercializes, and sells medicines and therapies worldwide. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
06-07-2025
- Business
- Globe and Mail
2 Dividend Stocks to Buy for Decades of Passive Income
Key Points Healthcare giants AbbVie and Abbott Laboratories are both Dividend Kings. They should maintain their dividend growth habits for a long time to come. That's thanks to their solid businesses and promising product pipelines. In 2013, AbbVie (NYSE: ABBV) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (NYSE: ABT). Since then, both have produced strong returns and have been great picks for income-seeking investors, thanks to consistent payout hikes. That likely won't change soon. These healthcare leaders should continue to perform well and reward shareholders with dividend increases for a long time. Read on to find out more. 1. AbbVie AbbVie is a pharmaceutical leader with a large portfolio of approved products, none more important than a duo of immunology medicines: Skyrizi and Rinvoq. In the first quarter, the company's revenue increased by 8.4% year over year to $13.3 billion, while its adjusted earnings per share came in at $2.46, 6.5% higher than the year-ago period. These results are all the more impressive considering AbbVie faced a major patent cliff just two years ago; however, it has since recovered, largely thanks to Skyrizi and Rinvoq. The former generated $3.4 billion in sales during the period, representing a 70.5% year-over-year increase. Rinvoq's revenue came in at $1.7 billion, 57.2% higher than the year-ago period. Management predicts their combined annual sales will exceed $31 billion by 2027. Not only is that significantly higher than the $17.7 billion they racked up last year, it's also $4 billion higher than their previous guidance. Skyrizi and Rinvoq are expected to drive top-line growth well into the 2030s. Although they will eventually lose patent protection, they demonstrate AbbVie's ability to navigate even the biggest patent cliffs, a quality that is essential for any pharmaceutical company to thrive over the long term. AbbVie has other products that help drive revenue growth, and, equally important, it has a deep pipeline that it routinely strengthens through acquisitions. In March, the company announced a licensing deal with Denmark-based Gubra A/S for GUB014295, an investigational weight management therapy. AbbVie paid $350 million up front for this candidate, with potential milestones of $1.9 billion, not including royalties. AbbVie entered the fast-growing weight loss market with this move; GUB014295 might not pan out, but AbbVie's large pipeline, with approximately 90 products in development, should allow it to launch brand-new products frequently, navigate patent cliffs, and remain successful over the long run. Now turning to the company's dividend, AbbVie has increased its payouts by 310% since 2013. And counting the time it spent under Abbott Laboratories' name, AbbVie is a Dividend King with 53 consecutive years of payout increases. These facts, from AbbVie's underlying business to the company's dividend track record, point to a company capable of sustaining a passive income program for a long time. 2. Abbott Laboratories Abbott Laboratories is best known for its leadership in the medical device space, where it markets dozens of products across multiple therapeutic areas. The company also operates a diagnostic business and has a presence in the pharmaceutical and nutrition industries. Abbott Laboratories' operations are diversified, which can help it overcome challenges in specific segments. That's one of the company's strengths. Here's another: Abbott Laboratories has been a leader in the highly regulated healthcare sector for decades. The company has built a solid reputation with physicians and consumers, all of whom are more likely to gravitate toward the brands they know and trust. In the medical device field, Abbott is a trusted brand. And thanks to its vast portfolio, it generates consistent revenue and earnings. Abbott's biggest growth driver in recent years has been its diabetes care segment, led by its continuous glucose monitoring (CGM) franchise, the FreeStyle Libre. As the company noted, the FreeStyle Libre has become the most successful medical device in history in terms of dollar sales. That's no small feat. Yet there is still massive whitespace ahead, since only a small portion of the world's diabetics use CGM technology despite its advantages. Abbott's work in this niche should provide a powerful long-term tailwind, but there will be many others. The company boasts other growth drivers, including its structural heart segment, where it markets a range of successful devices, such as its MitraClip device, a leader in its mitral valve repair niche. Beyond any single product, Abbott Laboratories has a proven track record as an innovator and should continue launching newer and better ones. Lastly, Abbott is also a Dividend King, and over the past decade, it has increased its payouts by almost 146%. Abbott Laboratories' business is built to last. Investors who purchase the company's shares today can expect consistent dividend growth over the long term. Should you invest $1,000 in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor 's total average return is1,060% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 30, 2025
